Abstract:Objective. During in vitro fertilization-embryo transfer (IVF-ET) treatment, the reproductive endocrine regulatory mechanisms hold pivotal importance. Specifically, the serum estradiol ( E2 ) level during ovulation emerges as a critical factor influencing pregnancy outcomes. This retrospective study aimed to comprehensively compare two common clinical regimens based on the grouping of serum E2 levels and the number of oocytes retrieved on the trigger day. Our objective was to evaluate the pregnancy outcomes in IVF-ET patients across different ovarian response groups, exploring the efficacy of the dual-trigger and single-trigger regimens to provide valuable insights for optimizing clinical strategies in the context of IVF-ET. Methods. A retrospective analysis was conducted on the clinical data of 2778 infertile patients who underwent ART (IVF/ICSI). Subsequently, a detailed statistical analysis was performed on 1032 patients following an antagonist regimen. Participants were categorized into single-trigger and dual-trigger groups based on real-world trigger protocols, considering different ovarian responses. Comprehensive statistical assessments were conducted on baseline characteristics, ovulation induction, and pregnancy outcomes. Results. Baseline characteristics and cycle parameters among the three patient groups (high ovarian response, normal response, and poor response) exhibited no significant differences between the dual-trigger and single-trigger regimen groups. Despite the dual-trigger regimen utilizing a significantly lower HCG dose, no notable discrepancies were observed in laboratory results and pregnancy outcomes (embryo transfer rate, pregnancy rate, and live birth rate) for normal and high responders. Remarkably, E2 levels were higher in the dual-trigger group compared to the single-trigger group. In high and normal responders, the dual-trigger regimen demonstrated increased oocyte counts and oocyte acquisition rates, coupled with decreased transfer cancellation rates attributed to ovarian hyperstimulation syndrome (OHSS). Intriguingly, patients with a poor ovarian response experienced no graft cancellations due to OHSS prevention in either group. Conclusion. For patients with high and normal ovarian responses, the utilization of a dual-trigger regimen on the trigger day effectively mitigates the risk of OHSS. Our large sample study supports the substitutability of the dual-trigger regimen over the single-trigger regimen without compromising pregnancy outcomes. However, this conclusion is not applicable to patients with poor ovarian responses. The results of this study highlight the necessity of adopting a customized and individualized treatment approach that should be based on the patient's ovarian response. Additionally, recognizing the pivotal role of the endocrine environment in influencing pregnancy outcomes and the occurrence of OHSS, further exploration of the effects of different triggering regimens on endocrine parameters is warranted. Such investigations will contribute to enhancing the reproductive outcomes of IVF-ET technology.

Application of Gonadotropin-Releasing Hormone Agonist Combined with Low Dose Human Chorionic Gonadotropin Trigger in the in Vitro Fertilization of High Responder

P-676 Comparison of Hcg Triggering Versus Hcg in Combination with a GnRH Agonist: a Prospective Randomized Controlled Trial

[Gonadotropin-Releasing Hormone Antagonist Protocol in Patients with Risk of Poor Response to Ovarian Stimulation in IVF-ET].

GnRHa combined with low dose hCG trigger in in vitro fertilization treatment of polycystic ovary syndrome high responders

Gonadotropin Releasing Hormone Agonist and Standard Dosage of Human Chorionic Gonadotropin Trigger Improve the in Vitro Fertilization and Embryo Transfer/intracytoplasmic Sperm Injection Treatment Prognosis of Patients with History of Poor Fertilization Outcomes

Co-administration of gonadotropin-releasing hormone agonist and recombined-human chorionic gonadotropin in patients with low proportion of mature oocytes during in vitro fertilization treatment

GnRH Agonist and hCG (Dual Trigger) Versus hCG Trigger for Final Oocyte Maturation in Expected Normal Responders With a High Immature Oocyte Rate: Study Protocol for a Randomized, Superiority, Parallel Group, Controlled Trial

Effect of GnRH agonist alone or combined with different low-dose hCG on cumulative live birth rate for high responders in GnRH antagonist cycles: a retrospective study

Effect of a “dual Trigger” Using a GnRH Agonist and Hcg on the Cumulative Live-Birth Rate for Normal Responders in GnRH-Antagonist Cycles

Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles

Association Between Luteinizing Hormone Level Decrease on the Triggering Day and Pregnancy Outcome for in Vitro Fertilization/intracytoplasmic Sperm Injection Patients Following Gonadotropin-Releasing Hormone Antagonist Protocol: a Retrospective Cohort Study

Effects Of Growth Hormone Supplementation In Poor Responders Undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection Treatment

GnRH agonist-only trigger, compared to dual trigger, reduces oocyte retrieval rate in high responders without affecting cumulative live birth rate

Comparison of HCG Trigger versus Dual Trigger in Improving Pregnancy Outcomes in Patients with Different Ovarian Responses: A Retrospective Study

Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve

GnRH Agonist and Hcg (dual Trigger) Versus Hcg Trigger for Follicular Maturation: a Systematic Review and Meta-Analysis of Randomized Trials

Effect of Dual Trigger In Vitro Fertilization and Intracytoplasmic Sperm Injection During the Gonadotropin-releasing Hormone-Antagonist Cycle on Final Oocyte Maturation and Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve

Comparison of the Clinical Outcomes of Using Three Different Trigger Programs in PCOS Patients Undergoing Artificial Insemination with Husband's Semen

Dual trigger of final oocyte maturation with a combination of GnRH agonist and hCG versus a hCG alone trigger in GnRH antagonist cycle for in vitro fertilization: A Systematic Review and Meta-analysis

Co-administration of GnRH-agonist and Hcg (double Trigger) for Final Oocyte Maturation Increases the Number of Top-Quality Embryos in Patients Undergoing IVF/ICSI Cycles.

Triggering oocyte maturation in IVF treatment in normal responders: a systematic review and network meta-analysis